A simple blood draw could spot bladder Cancer's return

NCT ID NCT07756437

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study is testing whether a blood test can find tiny pieces of tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer. Researchers will compare DNA from tumor tissue with DNA in blood samples taken during routine care. The goal is to see how well the test detects cancer-related mutations and whether it might predict recurrence or remission over two years. Participants do not receive any experimental treatment, and their doctors will not see the test results during the study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A blood-based circulating tumor DNA (ctDNA) test
What this could lead to
If successful, this blood test could help doctors detect cancer recurrence earlier and tailor treatments for bladder and upper tract cancers.
What could go wrong
This is an early-stage observational study, so the test may not prove accurate enough for routine use. It does not change treatment during the study, and results need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CANCER (MIBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AZ Sint-Lucas Gent

    RECRUITING

    Ghent, East Flanders, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.